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1. Introduction 
Osteosarcoma is the most frequent primary solid malignancy of bone. It is defined by the 
presence of malignant mesenchymal cells which produce osteoid or immature bone1,2. The 
incidence of osteosarcoma in the general population is only 2-3 per million per year. It is 
much higher in adolescents, where the annual incidence peaks at 8-11 per million at age 15-
19 years and the tumor accounts for more than 10% of all solid malignancies. Males are 
affected approximately 1.4 times more often than females3,4. High-grade osteosarcomas have 
a great propensity to metastasize. Primary as well as metachronous metastases usually 
involve the lungs or, less frequently, distant bones, while other sites are only rarely 
affected1,2,5,6. At diagnosis, even the most accurate staging procedures detect metastases in 
only 10-20% of patients, but without adequate treatment, most patients with seemingly 
localized disease will develop secondary metastases and die within one to two years1,2,5,6. 
With present day multimodality treatment, approximately 50- 70% of patients can hope to 
achieve long-term survival with an interdisciplinary treatment including surgery and 
multidrug chemotherapy7. 
Amputation had been the standard method of treatment for most bone sarcomas, but the 
1980s witnessed the development of limb-sparing surgery for most malignant bone tumors. 
Kenneth C. Francis at New York University and Ralph C. Marcove performed the original 
limb-sparing procedures in the United States8,9. Today, limb-sparing surgery is considered 
safe and routine, but demanding, for approximately 90% to 95% of patients with extremity 
osteosarcomas. Before routine use of systemic chemotherapy for the therapy of 
osteosarcoma, fewer than 20% of patients survived more than 5 years. Further, recurrent 
disease developed in 50% of patients, almost exclusively in the lungs, within 6 months of 
surgical resection. The findings of two randomized clinical studies completed in the 1980s 
comparing surgery alone to surgery followed by chemotherapy demonstrated conclusively 
that the addition of systemic chemotherapy improved survival in patients presenting with 
localized high-grade osteosarcoma. 
Prior to the use of neoadjuvant or adjuvant chemotherapy, 80 to 90 percent of patients with 
bone sarcomas developed metastases despite achieving local tumor control and died of their 
disease. It was demonstrated10 that subclinical metastatic disease was present at the time of 
diagnosis in the majority of patients and the use of chemotherapy can successfully eradicate 
these deposits if initiated at a time when disease burden is low. The benefit of adjuvant 
chemotherapy was demonstrated in two prospective randomized trials conducted in the 
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1980s in which the addition of postoperative chemotherapy improved survival in patients 
presenting with localized high-grade osteosarcoma when compared to surgery alone11,12,13. 
Chemotherapy is now considered a standard component of osteosarcoma treatment, both in 
children and in adults. In addition, up to 35 to 40 percent of those with limited pulmonary 
metastases may be cured with multimodality therapy. In contrast, long-term survival can be 
expected in less than 20 percent of all other patients who present with or develop overt 
metastatic disease. 
2. Historical aspect of chemotherapy in osteogenic sarcoma 
Neoadjuvant chemotherapy evolved in concert with the use of limb-salvage surgical 
approaches. At Memorial Sloan-Kettering Cancer Center, customized endoprosthetic devices 
in limb-salvage procedures often required several months to manufacture. Rather than 
delaying treatment, investigators began to administer chemotherapy while waiting for the 
endoprosthesis to be made. This approach led to suggestions that preoperative chemotherapy 
improved survival of the patients. In addition, orthopedic oncologists developed their own 
opinions regarding the advantages and disadvantages of presurgical chemotherapy 
3. Neoadjuvant versus adjuvant chemotherapy 
Chemotherapy is now considered a standard component of osteosarcoma treatment, both in 
children and in adults. The choice of regimen and optimal timing (i.e., preoperative versus 
postoperative) are controversial; however, many centers preferentially utilize preoperative 
chemotherapy, particularly if a limb-sparing procedure is being contemplated for an 
extremity osteosarcoma. 
These observations ultimately led to a randomized clinical study conducted between 1986 
and 1993 by the Pediatric Oncology Group (POG trial 8651) that compared immediate 
surgery and postoperative chemotherapy versus 10 weeks of the same chemotherapy 
regimen followed by surgery in 100 patients under the age of 30 with nonmetastatic high-
grade osteosarcoma14. Chemotherapy consisted of alternating courses of HDMTX with 
leucovorin rescue, cisplatin plus doxorubicin, and bleomycin, cyclophosphamide, and 
dactinomycin (BCD). The five-year relapse-free survival rates were similar between the two 
groups (65 versus 61 percent for adjuvant and neoadjuvant therapy, respectively) as was the 
limb salvage rate (55 and 50 percent for immediate and delayed surgery, respectively). 
The study was criticized for the relatively low rate of limb-sparing surgery in both groups 
(by modern standards) and the inclusion of BCD as a component of the regimen. The 
contribution of BCD to the therapeutic efficacy of this regimen is unclear, while it can clearly 
contribute to long-term bleomycin-related pulmonary toxicity 
Limb-sparing surgery — Due to its success in killing cancer cells (although actual tumor 
shrinkage during treatment is not common, particularly with chondroblastic 
osteosarcomas), neoadjuvant chemotherapy has evolved to a method of increasing the 
proportion of patients who are suitable candidates for limb-salvage surgery. The majority of 
limb-sparing surgical procedures for extremity osteosarcomas are now performed at 
institutions using presurgical chemotherapy. Neoadjuvant chemotherapy is never a 
substitute for sound surgical principles. 
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4. Response to neoadjuvant chemotherapy and its implications 
Initial chemotherapy response and individualizing postoperative therapy — One of the 
most compelling rationales for neoadjuvant chemotherapy is its ability to function as an in 
vivo drug trial to determine the drug sensitivity of an individual tumor and to customize 
postoperative therapy. Many grading system for assessing the effect of preoperative 
chemotherapy on the tumor has been developed. (Table 1)15 
 
Picci et al Huvos et al
Total response-No viable tumour IV-No histological viable tumour 
Good response- 90%-99% necrosis III- Scattered foci of viable tumour 
Fair response- 60%-89% necrosis II-Areas of necrosis with viable tumour 
Poor response-<60% necrosis I-Little or no chemotherapy effect 
Table 1. 
A consensus has emerged that uses greater than 90% necrosis and less than 90% necrosis as 
separating good and poor responses, respectively. Furthermore, most current studies use 10 
to 12 weeks of preoperative chemotherapy (Fig 1). 
 
Fig. 1. The preoperative biopsy demonstrates osteoblastic osteosarcoma that contains 
malignant spindle cells with abundant well-formed osteoid matrix (A). The sclerotic sheet-
like osteoid matrix with vascular channels is observed after chemotherapy (B, C), and viable 
tumor cells are remained among abundant eosinophilic matrix (D). 
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The IOR reviewed data on localized-extremity osteosarcoma in patients less than 40 years of 
age over the 19-year period from 1983 to 200216. More than 1,000 patient records were 
analyzed. Fifty-nine percent of all patients had a good response to chemotherapy, and 41% 
had a poor response. Patients with a good histologic response to chemotherapy had a 5-year 
survival of 76%, whereas those with a poor response had a 5-year survival rate of 56%. 
The COSS database was similarly reviewed and included 1,700 patients entered on study 
between 1980 and 1998. This analysis included all sites, ages, and presence or absence of 
metastases17. The data look remarkably similar to those of the Italian study, with 55.6% of 
patients classified as having a good response to therapy and 44.4% having a poor response. 
The 5-year survival rate was 77.8% for good responders and 55.5% for poor responders. Of 
further note, all the patients in both of these analyses received HD-MTX, and the majority 
also received ADM, CDDP, with or without IFOS. 
The European Osteosarcoma Intergroup (EOI) analyzed data for two consecutive studies 
between 1983 and 1986 and 1986 and 199118. A total of 570 patients were analyzed in the 
report. This analysis is notable for several differences compared to the COSS and IOR 
analyses. Only 28% of patients had a good histologic response, whereas 72% of patients had 
a poor histologic response. Patients with a good histologic response had a 5-year survival of 
75%, whereas those with a poor response had a 5-year survival of 45%. Of note, many of the 
patients included in the analysis did not receive HD-MTX because many were treated on a 
randomized study comparing two drugs, ADM and CDDP, to more intensive therapy 
including HD-MTX, similar to the COSS and IOR studies [Table 2]. The large randomized 
study failed to show an advantage of multiagent therapy compared to ADM and CDDP 
alone19. 
 
Trials No of PTS Good responders Poor responders HD-MTX used 
COSS 1700 56.6% 44.4% YES 
IOR 1000 59% 41% YES 
EOI 570 28% 72% NO 
Table 2. 
A factor that could possibly influence histologic response to therapy and its predictive value 
on survival is the histologic subtype of the tumor. In both studies, fibroblastic tumors had a 
higher rate of good histologic response (approximately 80% in the IOR study), whereas 
chondroblastic tumors had a lower rate of good responders (43% in the IOR study). Perhaps 
even more important, unlike other histologies, 5-year survival rates were identical for good 
and for poor responders in chondroblastic histology, at 68%. 
5. Modification of chemotherapy based on necrosis 
By knowing the histologic response to neoadjuvant therapy an exciting avenue of modifying 
post operative chemotherapy and hence attempting to improve survival in poor responders 
has opened. This has been earlier proven in hematolymphoid malignancy. In the early 1980s 
at Memorial Sloan-Kettering Cancer Center, poor responders had CDDP substituted for HD-
MTX in addition to continuing BCD (bleomycin, cyclophosphamide, and dactinomycin) and 
ADM20. Patients who had adjustments in their postoperative chemotherapy based on poor 
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initial response did not have improvement in survival compared to those who had no 
modifications21. Several other reports have also failed to demonstrate an ability to rescue 
poor responders22,23. Although tumor necrosis correlates with outcomes, detection of this 
feature at such a late stage may not offer the chance to target therapy, and therefore, better 
methods to identify chemoresistant tumors at diagnosis are needed. Thus, to date, it has not 
been possible to improve the outcome of poor responders by altering postoperative 
chemotherapy. 
6. Development of chemotherapy regimens 
The choice of chemotherapeutic agents has largely been empirical with most groups using 
ADM, CPL or High dose methotrexate(HD-MTX). 
Role of methotrexate — The role of HDMTX has been questioned (particularly in adults). 
There are no randomized studies that have shown an advantage for higher as compared to 
intermediate doses of methotrexate24 or for HDMTX plus doxorubicin and cisplatin versus 
doxorubicin/cisplatin alone25. Furthermore, investigators at St. Jude’s Hospital have 
demonstrated good outcomes (five-year event free and overall survival rates 66 and 75 
percent) with a non-methotrexate-containing chemotherapy regimen consisting of 
carboplatin plus ifosfamide and doxorubicin26. 
On the other hand, a benefit for HDMTX is supported by at least one series that 
demonstrates a superior outcome with high-dose as compared to intermediate-dose 
methotrexate in the context of a multiagent chemotherapy regimen. Furthermore, many 
studies have shown a correlation between peak serum levels of methotrexate, tumor 
response, and outcome27-30. Thus, it is possible that determining a benefit for HDMTX has 
been compromised by the use of insufficient doses31 or administration schedules. The role of 
HDMTX in chemotherapy for osteosarcoma requires further study32. 
Benefit of ifosfamide-based therapy and mifamurtide — The upfront addition of 
ifosfamide with or without etoposide to HDMTX, doxorubicin, and cisplatin improves 
initial tumor response rates, but the influence on overall and event-free survival is unclear33-
37. The benefit of ifosfamide and the liposomal formulation of immune stimulant muramyl 
tripeptide phosphatidylethanolamine (MTP-PE, mifamurtide, Junovan) were evaluated in a 
large phase III study involving 677 patients with nonmetastatic osteosarcoma33. All patients 
received doxorubicin, cisplatin, and methotrexate, and were randomized in a 2 x 2 scheme 
to receive or not receive ifosfamide, and then to receive or not receive liposome 
encapsulated mifamurtide. 
The addition of ifosfamide-based therapy improved the relapse-free survival rate, but only 
when used in conjunction with the mifamurtide. Thus, the routine addition of ifosfamide to 
adjuvant chemotherapy for osteosarcoma is not recommended outside of a clinical trial 
However, the use of mifamurtide improved survival, which led to European regulatory 
approval of this agent for patients with osteosarcoma38. 
Chemotherapy for adults - In many (but not all series, adults, especially older adults, have a 
worse prognosis than children with osteosarcoma. This was shown in a population-based 
series from the Surveillance, Epidemiology, and End Results (SEER) database of the 
National Cancer Institute39. Adults are most often offered doxorubicin plus cisplatin, 
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although the role of HDMTX remains a major unanswered question. For patients under the 
age of 35, we often employ all three agents, while for older patients, in whom the biology of 
the tumor may be somewhat different, we generally employ doxorubicin and cisplatin only, 
given the lack of difference between cisplatin/doxorubicin and the more complex T10-type 
regimen in the adjuvant setting in one study. 
7. Chemotherapy in metastatic disease  
Optimal management for patients who present with metastatic osteosarcoma has not been 
defined by randomized clinical trials, and thus, there is no single standard approach. The 
most active drugs in patients with measurable disease (HDMTX, doxorubicin, cisplatin, 
ifosfamide) have single-agent response rates between 20 and 40 percent40-45. Response rates 
are higher with multiagent regimens but a lower proportion of patients treated for 
metastatic disease show a good histological response to neoadjuvant chemotherapy as 
compared to those with apparently localized disease This suggests an underlying difference 
in the biological behavior. 
In an effort to improve outcomes, the Pediatric Oncology Group and others have utilized a 
strategy of applying novel agents to patients with newly diagnosed metastatic disease prior 
to standard therapy (termed the "therapeutic window" approach)40,42,46,47. Using this 
approach, POG identified the combination of ifosfamide/etoposide as effective induction 
therapy, particularly for those with metastatic bone disease. Thus, although there is no 
accepted standard approach for the treatment of newly diagnosed metastatic patients, 
available data would suggest that such patients should be treated with currently available 
aggressive multiagent chemotherapy with complete surgical resection of all sites of disease 
if at all possible. 
Nevertheless, few patients with metastatic osteosarcoma are cured, and new therapeutic 
approaches are needed. For patients who present with overt metastatic disease, 
participation in experimental trials should be encouraged.  
A study evaluating the feasibility of adding trastuzumab to standard chemotherapy for 
patients whose tumors are HER2 positive was just completed by the Children's Oncology 
Group (COG)48. The results of this study are not yet available.Numerous in vitro and 
xenograft studies support the concept that bisphosphonates have activity against 
osteosarcoma alone or in combination with chemotherapy49. 
8. Treatment of recurrent disease 
Patients with a disease recurrence after resection alone can often be salvaged with additional 
surgery and chemotherapy, although their long-term survival is inferior to that of patients 
who received conventional multiagent chemotherapy in conjunction with surgery 
upfront50,51. 
Treatment of relapse in patients who have already received adjuvant and/or neoadjuvant 
chemotherapy is a more difficult situation. Such patients usually have received most of the 
effective drugs, and presumably their tumors are more chemotherapy-resistant than those 
that have never been exposed to antineoplastic agents52. 
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Salvage is still possible and is more likely in patients with a longer relapse-free interval. In a 
large database of 565 osteosarcoma patients who relapsed after being treated on one of three 
different neoadjuvant chemotherapy protocols within the European Osteosarcoma 
Intergroup, five year survival postrelapse in those whose disease recurred after two years 
versus within two years of randomization was 35 versus 14 percent, respectively53. Other 
favorable prognostic factors in recurrent osteosarcoma include no more than one or two 
pulmonary nodules, the presence of unilateral pulmonary involvement, lack of pleural 
disruption, and achieving a second surgical remission,50,54-56. In general, patients should be 
treated with any of the four most active agents noted earlier if initial therapy did not include 
one or more of these agents. Patients who have recurrences more than 1 year after 
completing prior systemic therapy may benefit from reintroduction of at least some of the 
same drugs in a salvage regimen. The use of high-dose chemotherapy with autologous 
hematopoietic stem cell rescue has been applied to salvage therapy. However, at least two 
small pilot studies failed to demonstrate an advantage to standard salvage therapy 
approaches57,58.  
9. Newer and investigational approaches 
A study of the mTOR inhibitor ridaforolimus in patients with metastatic sarcoma suggests 
potential activity for this class of compounds in patients with osteosarcoma59, raising the 
possibility of using these and other kinase-targeted agents in patients with metastatic 
disease. If activity is confirmed, it is expected that these agents will be studied in the 
adjuvant setting as well. 
Among other interesting agents that may have clinical utility are inhibitors of insulin-like 
growth factor I receptor (IGF IR), since IGF signaling is critical for bone formation during 
development. Early studies with a variety of monoclonal antibodies and small molecule 
inhibitors of the IGF IR are underway. 
Immunotherapy — Immune responses may influence the survival of patients with 
osteosarcoma. Cytotoxic lymphocytes are present in such patients60,61, and in at least one 
study, the degree of lymphocytic infiltration correlated with survival61. These findings have 
prompted investigators to explore a variety of immunotherapeutic approaches for patients 
with advanced osteosarcoma. 
The addition of Bacille Calmette-Guerin (BCG) and interferon did not improve survival 
when added to multiagent chemotherapy62,63. However, encouraging preliminary results 
were obtained using liposomal muramyl tripeptide-phosphatidyl-ethanolamine 
(mifamurtide), an agent derived from BCG that activates macrophages and increases 
circulating cytokine levels64,65. These data led to a randomized study, described above, in 
which patients were assigned, using a 2 x 2 factorial design, to standard chemotherapy with 
or without ifosfamide and then to receive or not receive mifamurtide. The addition of 
mifamurtide to standard chemotherapy resulted in a statistically significant improvement in 
overall survival (78 versus 70 percent at six years) and a trend toward improved event-free 
survival (67 versus 61 percent)  
However, when the analysis was restricted to the 91 patients with metastatic disease at 
diagnosis, there was only a nonstatistically significant trend toward improved five-year 
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event free survival (42 versus 26 percent) and overall survival (53 versus 40 percent) that 
favored mifamurtide66. The drug is not available in the United States. Thus, the role of 
mifamurtide in patients with metastatic osteosarcoma remains uncertain and a further 
randomized trial seems warranted. 
Another immunotherapeutic approach that is being pursued for pulmonary metastatic 
disease is inhalation of aerosolized granulocyte macrophage colony-stimulating factor (GM-
CSF). GM-CSF stimulates the proliferation and differentiation of hematopoietic progenitor 
cells and augments the functional activity of neutrophils, monocytes, macrophages, and 
dendritic cells. Recombinant GM-CSF has been used primarily to enhance neutrophil 
recovery after chemotherapy.  
Preclinical as well as early clinical studies suggest that locally applied GM-CSF may provide 
antitumor effects67,68. These data form the basis for novel therapeutic vaccine approaches 
using irradiated tumor cells or dendritic cells that are genetically engineered to produce 
GM-CSF locally and provide the rationale to explore local application of GM-CSF in other 
diseases. 
Local application to the lungs (the most common site of metastatic disease) through 
inhalation of GM-CSF has been studied. Early data using aerosolized GM-CSF (250 
micrograms per dose, twice daily) in a variety of cancers with pulmonary metastases 
suggest that this approach is safe and possibly effective; in one study, a patient with 
metastatic Ewing sarcoma had a complete response to therapy69,70. In at least one case, 
upregulation of tumor-specific cytotoxic T lymphocytes has been shown. 
Inhaled GM-CSF was evaluated in 43 patients with pulmonary relapse from 
osteosarcoma in the American Osteosarcoma Study Group [AOST] protocol 022171. 
Inhaled G-CSF was administered at doses from 250 to 1750 microg twice daily every 
other week; after four weeks, resection was performed, and G-CSF was resumed for an 
additional 24 weeks or until progression. Although doses as high as 1750 microg twice 
daily were feasible with no dose-limiting toxicity, there was no detectable 
immunostimulatory effect on the pulmonary metastases or suggestion of improved 
outcomes post relapse (three-year event-free and overall survival rates were 8 and 35 
percent, respectively). 
10. Intra-arterial chemotherapy 
The introduction of neoadjuvant chemotherapy into the multi-modality of treatment of 
osteosarcoma is the most important advancement in treatment of the disease. However, for 
the last 10 years, there has been less significant improvement in survival with the use of 
multiagent neoadjuvant chemotherapy. In these patients, the extent of chemotherapy-
induced tumor necrosis is strictly correlated with prognosis. To increase the rate of 
chemotherapy-induced tumor necrosis, delivery of larger doses of drugs to the primary 
tumor has been attempted using intraarterial chemotherapy. Of the drugs which are 
effective in osteosarcoma, cisplatin is considered the most suitable for intraarterial infusion 
because intraarterial cisplatin is not associated with a significant local reaction and systemic 
drug levels are not compromised by intraarterial infusion72,73.  
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The COSS-86 study was the only prospective controlled study designed to verify whether 
intraarterial infusion of cisplatin was more effective than intravenous infusion in a 
multiagent pre-operative chemotherapy setting. In this study, intraarterial or intravenous 
cisplatin were given with HD-MTX, adriamycin and ifosfamide and the response rate and 
10-year event free survival were also identical. The authors themselves suggested that a 
selection bias may have influenced outcome. 
In Bacci et al’s study, the doses and the time infusion of cisplatin were the same for 
patients treated intraarterially and intravenously. When used within a three-drug 
regimen (HD-MTX, cisplatin, adriamycin), intraarterial cisplatin was significantly more 
effective on the primary tumor than the intravenous infusion. When cisplatin was 
delivered within a four-drug regimen (HD-MTX, cisplatin, adriamycin and ifosfamide), 
which significantly increased the good responses, the advantage of intraarterial cisplatin 
disappeared74.. Therefore, it seems that the addition of another active drug to cisplatin 
and adriamycin concealed the difference. The Instituto Ortopedico Rizzoli (IOR-OS) 2 
and 3 studies demonstrated that the rate of histological response was significantly higher 
in the intraarterial cisplatin regimen than the IV regimen75. Apart from histologic 
necrosis, response evaluation can also be done with pre and post chemotherapy 
angiograms [Fig. 2]. 
However there is lack of randomized trials of intraarterial chemotherapy in osteogenic 
sarcomas to draw any definitive conclusions on this promising modality of treatment. 
Future endeavors should involve a multi-institutional randomized study comparing this 
approach with another multiagent intravenous neoadjuvant protocol. 
   
Fig. 2. (A) A radiogram of a man with osteosarcoma of the distal femur.  
(B) An arteriogram after the first course of chemotherapy shows viable tumor area with 
tortuous vessels and intense contrast uptake.  
(C) An arteriogram after the fourth course shows a decrease in contrast uptake with little 
evidence of residual tumor staining. It was estimated that there was > 90% decrease in 
neovascularity. 
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11. Conclusion 
Chemotherapy in osteogenic sarcoma has remarkable impact evident by the fact that 
survival has increased from dismal 20% in pre-chemotherapy era to respectable 60% in 
present era.The impact of chemotherapy in Limb salvage approach is tremendous with limb 
salvage rates around 90-95% at most referral centres. The optimal regimen and timing 
(Neoadjuvant vs Adjuvant) of chemotherapy needs to be defined. The strategy of 
chemotherapy modification based on percentage necrosis after pre-op chemotherapy needs 
further clarification. 
Despite impressive 60% survival in most western centers, the survival data of osteogenic 
sarcoma is not so encouraging in developing countries. The overall 5- and 10-year survival 
rates in the Brazilian osteosarcoma study group were lower than the rates reported in North 
American and European trials. A pattern of advanced disease at diagnosis was often 
present, with a high proportion of patients having metastases (20.8%) and large tumor size 
(42.9%)76.The developing countries have low limb salvage rates secondary to non 
availability of costly hardware  along with few referral centers with expertise to administer 
high dose Methotrexate.  Development of indigenous, low cost and durable implants77 and 
less costly effective chemotherapy78 is needed to optimally treat this disease in developing 
countries. More patients need to be enrolled in randomized clinical trials testing optimal 
regimen, timing and low cost implants. Newer molecules in research pipeline provide ray of 
hope for metastatic and relapsed osteogenic sarcoma. 
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